secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001125345-25-000054
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics Q1 2025 net loss improves to $41M; cash runway into H2 2026
-----------------------------------------------------------------------

- Net loss of $41.0M ($0.65 loss per share) vs Q1 2024 loss of $52.2M ($0.84).
- Revenue $13.2M, up from $9.1M, driven by collaborative agreements and contract manufacturing; no product sales after MARGENZA sale.
- Cash, equivalents and marketable securities $154.1M as of Mar 31, 2025, down from $201.7M at Dec 31, 2024; runway projected into H2 2026.
- First patient dosed in Phase 2 LINNET study of lorigerlimab in platinum-resistant ovarian and clear cell gynecologic cancers.
- LORIKEET Phase 2 (lorigerlimab + docetaxel in mCRPC) clinical update expected in second half of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534525000054/0001125345-25-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534525000054/mgnx-20250513.htm
  HTML page:      https://secwatch.observer/filing/0001125345-25-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer